Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 8/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 7/20 | 0.34 |
| ▸ | CTSB | P07858 | 6/20 | 0.34 |
| ▸ | CTSK | P43235 | 6/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22713255 | 1.00 | CTSL (0.36) | CTSLHDAC6CTSSCTSBCTSK | |
| SCHEMBL25180313 | 1.00 | CTSL (0.36) | CTSLHDAC6CTSSCTSBCTSK | |
| SCHEMBL29504005 | 1.00 | CTSL (0.36) | CTSLHDAC6CTSSCTSBCTSK | |
| SCHEMBL22713253 | 1.00 | CTSL (0.36) | CTSLHDAC6CTSSCTSBCTSK | |
| SCHEMBL25180311 | 1.00 | CTSL (0.36) | CTSLHDAC6CTSSCTSBCTSK | |
| SCHEMBL22713257 | 1.00 | CTSL (0.36) | CTSLHDAC6CTSSCTSBCTSK | |
| SCHEMBL25180304 | 0.87 | CTSL (0.34) | CTSLCTSSCTSBCTSK | |
| SCHEMBL25180305 | 0.87 | CTSL (0.34) | CTSLCTSSCTSBCTSK | |
| SCHEMBL23898828 | 0.87 | CTSL (0.34) | CTSLCTSSCTSBCTSK | |
| SCHEMBL21273220 | 0.85 | CTSK (0.37) | CTSLCTSSCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150981-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-18 | — | — | US | disclosed |
| WO-2021202781-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150981-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | SSTR4, SSTR3, SSTR5 | CTSL 1777/4885HDAC6 1397/4885CTSS 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.